Key Takeaways
- Fertility labs handling donor tissue may need FDA registration as a tissue establishment even if they already hold CLIA certification.
- Donor eligibility determinations require specific FDA-licensed screening tests and documented review by a designated responsible person.
- State laws and accreditation standards often impose requirements beyond federal baselines, so compliance programs must account for multiple frameworks.
- Strong documentation practices are essential — records must allow third parties to reconstruct eligibility determinations years later.
Fertility labs that work with donor eggs, sperm or embryos devote substantial attention to donor eligibility, communicable disease testing and documentation. Yet compliance problems often surface long after a specimen has been accepted, such as when an inspector, accreditor or purchaser asks the lab to explain how a donor eligibility determination was made or to reconstruct the supporting documentation. FDA regulations, state law and accreditation standards do not always ask the same questions or require the same documentation.
Four areas deserve particular attention when evaluating donor tissue compliance.
1. CLIA and FDA differentiation
Any facility that recovers, processes, stores or distributes human cells, tissues, or cellular and tissue-based products may be required to register with the FDA as a tissue establishment under 21 CFR Part 1271. Fertility labs sometimes assume that because they operate under CLIA or a state clinical laboratory license, the tissue registration requirement does not apply. It does, and the determination turns on what they do with the tissue, not what kind of license they hold. For example, a fertility lab may already hold a CLIA certification for purposes of performing communicable disease testing while separately requiring FDA tissue establishment registration because it stores or distributes donor reproductive tissue.
2. Donor eligibility determinations
The donor eligibility requirements under 21 CFR 1271 Subpart C involve a donor screening questionnaire and specific communicable disease testing. The testing must be performed using FDA-licensed, approved or cleared donor screening tests, and the results must be reviewed and documented by the responsible person designated in the lab’s standard operating procedures.
3. State-level requirements can exceed the federal baseline
Several states impose additional requirements for reproductive tissue handling, including specific informed consent obligations, record retention periods and reporting requirements that go beyond what the FDA mandates. A compliance program built solely around federal requirements may not satisfy state requirements, depending on where the lab operates or where its donors and recipients are located.
4. Accreditation standards continue to evolve independent of regulatory requirements
Organizations such as the College of American Pathologists and Association for the Advancement of Blood & Biotherapies have been updating their reproductive tissue standards to reflect evolving clinical practices, including expectations around chain-of-custody documentation, labeling accuracy and storage monitoring. Even if the lab’s regulatory obligations have not changed, its accreditation obligations may have.
What this looks like in practice
Problems with donor eligibility records are often mundane: A donor test performed outside the required time frame, a missing linkage between a questionnaire and a specific specimen, an unclear record of who made the final eligibility determination, or a storage and labeling step that was handled correctly but documented incompletely.
The Readout
When donor tissue compliance processes fail, the consequences tend to be immediate and expensive. Clinics face delayed cycles and patient frustration when specimens are quarantined pending clarification. Labs absorb rework costs and leadership time during inspections and accreditation follow-up. In transactions, diligence teams treat reproductive tissue compliance issues as enterprise risk because documentation deficiencies raise questions about donor eligibility, operational controls and future regulatory risk.
Donor tissue compliance depends on documentation that allows someone else to understand how a determination was made months or years earlier. The fertility labs that stay ahead of these issues build documentation processes that remain reliable despite staff turnover, vendor changes and the passage of time.
The Lab Protocol is for informational and educational purposes only and does not constitute legal, regulatory or compliance advice. Readers should consult qualified counsel regarding their specific circumstances.